Torii Pharmaceutical Co., Ltd. (TRXPF)
- Previous Close
24.57 - Open
24.57 - Bid --
- Ask --
- Day's Range
24.57 - 24.57 - 52 Week Range
24.57 - 24.57 - Volume
100 - Avg. Volume
0 - Market Cap (intraday)
699.486M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
25.86 - EPS (TTM)
0.95 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
--
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
www.torii.co.jp583
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: TRXPF
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRXPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRXPF
Valuation Measures
Market Cap
684.32M
Enterprise Value
401.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.01
Enterprise Value/EBITDA
0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
7.54%
Return on Assets (ttm)
2.36%
Return on Equity (ttm)
3.44%
Revenue (ttm)
54.64B
Net Income Avi to Common (ttm)
4.12B
Diluted EPS (ttm)
0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
44B
Total Debt/Equity (mrq)
0.20%
Levered Free Cash Flow (ttm)
-8.72B
Company Insights: TRXPF
TRXPF does not have Company Insights